EICHOR
● Enrolling By Invitation
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
Condition: Becker Muscular Dystrophy · Sponsor: Edgewise Therapeutics, Inc.
About this study
EDG-5506-203 MESA is an open-label extension study to assess the long-term effect of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults and adolescents with Becker muscular dystrophy
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (46)
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | — |
| UC San Diego | La Jolla, California, United States | — |
| UCLA Medical Center | Los Angeles, California, United States | — |
| UC Irvine Medical Center | Orange, California, United States | — |
| Stanford Neuroscience Health Center | Palo Alto, California, United States | — |
| UC Davis Medical Center | Sacramento, California, United States | — |
| UC Denver | Aurora, Colorado, United States | — |
| University of Florida | Gainesville, Florida, United States | — |
| Rare Disease Research | Atlanta, Georgia, United States | — |
| Northwestern University | Chicago, Illinois, United States | — |
| Indiana University School of Medicine | Indianapolis, Indiana, United States | — |
| University of Iowa | Iowa City, Iowa, United States | — |
+ 34 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.